Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimisation of treatment in patients with CRSwNP (FESSnonFESS)
2024-514632-24-02Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Rigshospitalet. Primary endpoints: Change in SNOT-22 score, Change in nasal polyp score and 1 more. Planned start Aug 2024; status: authorised.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2024-514632-24-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514632-24-02.